1. Author's Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627. (2nd December 2022) Authors: Young-Xu, Yinong; Melsheimer, Richard; Emond, Bruno; Lefebvre, Patrick; DerSarkissian, Maral; Lax, Angela; Nguyen, Catherine; Bhak, Rachel H.; Wu, Melody; Lin, Iris Journal: Current medical research and opinion Issue: Volume 38:Number 12(2022) Page Start: 2237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. (3rd April 2022) Authors: Lin, Iris; Melsheimer, Richard; Bhak, Rachel H.; Lefebvre, Patrick; DerSarkissian, Maral; Emond, Bruno; Lax, Angela; Nguyen, Catherine; Wu, Melody; Young-Xu, Yinong Journal: Current medical research and opinion Issue: Volume 38:Number 4(2022) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LB1531B. Administration of the TNF-alpha inhibitor, infliximab, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial. (15th December 2022) Authors: O'Halloran, Jane A; Anstrom, Kevin J; Kedar, Eyal; McCarthy, Matthew W; Ko, Emily R; Melsheimer, Richard; Boucher, Cynthia; Chang, Soju; Bozzette, Samuel; Powderly, William G Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗